MetaCap

CytomX Therapeutics Insider Trades

NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.03-0.02 (-0.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
5 · $1.23M
Shares bought / sold
0 / 192.69K
Net activity
Net selling $1.2 million

CytomX Therapeutics insider activity

Over the last 12 months, CytomX Therapeutics insiders reported 11 transactions on SEC Form 4: 0 open-market purchases and 5 sales. Insiders bought $0 and sold $1.2 million worth of stock, for net insider selling of $1.2 million. The largest seller was McCarthy Sean A., with $764,138 in reported sales.

The most recent filing shows Carvajal Alejandra (Chief Legal Officer) reporting a transaction in 100,000 shares on Aug 3, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put CTMX's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

CTMX insider transactions

CytomX Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Aug 3, 2026Carvajal AlejandraChief Legal OfficerAward100,000—Form 4
Jun 15, 2026Ogden ChristopherChief Financial OfficerSale1,624$4.95KForm 4
Mar 17, 2026Ogden ChristopherChief Financial OfficerSale19,323$124.11KForm 4
Mar 17, 2026BELVIN MARCIASVP, Chief Scientific OfficerSale31,492$202.27KForm 4
Mar 17, 2026McCarthy Sean A.CEOSale118,969$764.14KForm 4
Mar 17, 2026Chu Yu-WayeChief Medical OfficerSale21,279$136.68KForm 4
Feb 2, 2026McCarthy Sean A.CEOAward210,000—Form 4
Feb 2, 2026Ogden ChristopherChief Financial OfficerAward90,000—Form 4
Feb 2, 2026BELVIN MARCIASVP, Chief Scientific OfficerAward60,000—Form 4
Feb 2, 2026Chu Yu-WayeChief Medical OfficerAward75,000—Form 4
Feb 2, 2026Lester RachaelChief Business OfficerAward20,000—Form 4
Nov 6, 2025McCarthy Sean A.CEOSale101,793$461.91KForm 4
Nov 6, 2025McCarthy Sean A.CEOSale101,793$461.91KForm 4
Nov 6, 2025McCarthy Sean A.CEOOption exercise101,793$161.85KForm 4
Jun 16, 2025BELVIN MARCIASVP, Chief Scientific OfficerSale13,884$37.33KForm 4
Jun 16, 2025Ogden ChristopherChief Financial OfficerSale10,614$28.54KForm 4
Jun 16, 2025McCarthy Sean A.CEOSale55,511$149.26KForm 4
Jun 13, 2025BELVIN MARCIASVP, Chief Scientific OfficerOption exercise37,500—Form 4
Jun 13, 2025Ogden ChristopherChief Financial OfficerOption exercise37,500—Form 4
Jun 13, 2025Ogden ChristopherChief Financial OfficerSale1,641$4.84KForm 4
Jun 13, 2025McCarthy Sean A.CEOOption exercise150,000—Form 4
Mar 18, 2025BELVIN MARCIASVP, Chief Scientific OfficerSale19,512$11.69KForm 4
Mar 18, 2025ROWLAND LLOYD AGeneral CounselSale10,203$6.11KForm 4
Mar 18, 2025McCarthy Sean A.CEOSale37,656$22.56KForm 4
Mar 18, 2025Chu Yu-WayeChief Medical OfficerSale4,025$2.41KForm 4
Mar 18, 2025Ogden ChristopherChief Financial OfficerSale8,551$5.12KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related